Enrichment for chemoresistant ovarian cancer stem cells from human cell lines

Journal of Visualized Experiments

Volumn , Issue 91, 2014, Pages

  Cole, Jennifer M ^a   Joseph, Stancy ^a   Sudhahar, Christopher G ^a   Cowden Dahl, Karen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer progression; Cancer stem cells; Chemoresistance; Cisplatin; Issue 91; Medicine; ovarian cancer; Stem cell markers

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CULTURE MEDIUM; TUMOR MARKER;

CANCER STEM CELL; CULTURE MEDIUM; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; MULTICELLULAR SPHEROID; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; CULTURE MEDIA, SERUM-FREE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84908337673     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51891     Document Type: Article

References (12)

1. Pennington, K., Pulaski, H., Pennington, M.., & Liu, J. R. Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma. Curr Cancer Drug Targets. 10, 575-83 doi:EPub-Abstract-CCDT-49 [pii] (2010).
2. Thigpen, T. A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol. 55, 114-130 doi:10.1097/GRF.0b013e31824b9bc5 (2012).
3. Burgos-Ojeda, D., Rueda, B. R.., & Buckanovich, R. J. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer letters. 322, 1-7 doi:10.1016/j.canlet.2012.02.002 (2012).
4. Ma, L., Lai, D., Liu, T., Cheng, W.., & Guo, L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). 42, 593-602 doi:10.1093/abbs/gmq067 (2010).
5. Bonnet, D.., & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine. 3, 730-737 (1997).
6. Alison, M. R., Lim, S. M.., & Nicholson, L. J. Cancer stem cells: problems for therapy? The Journal of pathology. 223, 147-161 doi:10.1002/path.2793 (2011).
7. Luo, X., Dong, Z., Chen, Y., Yang, L.., & Lai, D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell proliferation. 46, 436-446 doi:10.1111/cpr.12038 (2013).
8. Wang, L., Mezencev, R., Bowen, N. J., Matyunina, L. V.., & McDonald, J. F. Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Molecular and cellular biochemistry. 363, 257-268 doi:10.1007/s11010-011-1178-6 (2012).
9. Abubaker, K. et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Molecular cancer. 12, 24 doi:10.1186/1476-4598-12-24 (2013).
10. Conic, I., Dimov, I., Tasic-Dimov, D., Djordjevic, B.., & Stefanovic, V. Ovarian epithelial cancer stem cells. ScientificWorldJournal. 11, 1243-1269 doi:10.1100/tsw.2011.112 (2011).
11. Liu, K. C. et al. Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor. Oncotarget. 4, 12, 2366-2382 (2013).
12. Liu, T., Cheng, W., Lai, D., Huang, Y.., & Guo, L. Characterization of primary ovarian cancer cells in different culture systems. Oncology reports. 23, 1277-1284 (2010).